Skip to main content

Table 1 Rash rating scales used in this investigation

From: Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Grade

EGFR-Inhibitor induced rash scale

CTCAE Assessment scale

0

No rash

No rash

1

Isolated pustule or erythematous patch < 1 cm in diameter, on either face/head/neck or chest/back

Macular or papular eruption or erythema without associated symptoms

2

More than one erythematous patch or erythema and telangiectasia on either face/head/neck or chest/back

Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering < 50% of body surface area

3

More than one pustule or papules on either face/head/neck or chest/back with no associated erythema or telangiectasia

Severe, generalized erythroderma or macular, papular or vesicular eruption; desquamation covering ≥ 50% body surface area

4

Both erythema/telangiectasia and pustules/papules limited to either face/head/neck or chest/back

Generalized exfoliative, ulcerative, or bullous dermatitis

5

Pustules or papules and erythema/telangiectasia present on both the face/head/neck region and the chest/back

Death